Retatrutide Advanced Weight Loss Protocol

Achieve maximum fat loss in treatment-refractory obesity through triple GIP/GLP-1/glucagon receptor co-agonism, while preserving lean muscle mass, protecting GI tolerability, and supporting immune function during rapid weight reduction.

Patient profile: Adults with BMI ≥30, or BMI ≥27 with at least one obesity-related comorbidity (T2DM, hypertension, dyslipidaemia, MASLD, sleep apnoea). Suitable for patients who have failed on semaglutide or tirzepatide. Must be under physician supervision with metabolic monitoring capability.

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol →

⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

Retatrutide

Primary

Dose

0.5 → 12 mg (titrace)

Frequency

1× per week SC

Timing

Fixed day each week, same time, rotate injection sites (abdomen/thigh/upper arm)

Duration

48 weeks: 0.5 mg wk 1–4 → 1 mg wk 5–8 → 2 mg wk 9–12 → 4 mg wk 13–16 → 8 mg wk 17–20 → 12 mg wk 21–48

BPC-157

Supporting

Dose

250–500 mcg

Frequency

Daily SC

Timing

Morning, during titration phases (weeks 1–20); can be used as needed for GI flares at higher doses

Duration

Continuous throughout titration; optional maintenance at 3×/week from week 21

Thymosin Alpha-1

Optional

Dose

1.6 mg

Frequency

2× per week SC

Timing

Any time; avoid on days of Retatrutide injection if injection fatigue is a concern

Duration

Weeks 5–48 (introduce after initial GI tolerance confirmed)

Monitoring Parameters

✓Baseline: body weight, waist circumference, BMI, body composition (DEXA if available), fasting glucose, HbA1c, lipid panel, liver enzymes (ALT/AST), amylase/lipase, TSH, resting HR and BP
✓Every 4 weeks (titration phase): body weight, BP, resting HR — watch for glucagon-driven tachycardia (HR >100 bpm triggers dose hold)
✓Week 12: fasting glucose, HbA1c, lipid panel, liver enzymes, amylase/lipase
✓Week 24: full metabolic panel + body composition repeat
✓Week 48: full baseline panel repeat + body composition; decide on maintenance vs. taper
✓Protein intake tracking: target ≥1.6 g/kg lean body mass — reduced appetite increases sarcopenia risk
✓Thyroid monitoring (TSH) at baseline, week 24, and week 48 — GLP-1 class signal

Expected Outcomes

Weeks 1–8 (low-dose titration): nausea, reduced appetite; 2–4% weight loss expected

Weeks 9–20 (dose escalation): progressive weight loss accelerating; target 8–15% total at week 20

Weeks 21–48 (maintenance at 8–12 mg): continued weight loss slowing; Phase 2 data showed ~24.2% mean weight reduction at 48 weeks

Metabolic improvements: HbA1c reduction 1–2%, LDL reduction ~15–20%, triglyceride reduction ~30–40%

Hepatic steatosis: glucagon component expected to reduce liver fat (MASLD patients benefit most)

Lean mass: preserved with adequate protein intake; resistance training strongly recommended throughout

Contraindications

✗Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome
✗Active or history of recurrent pancreatitis
✗Resting tachycardia (HR >100 bpm) — glucagon component elevates heart rate; resolve before starting
✗Significant cardiovascular disease with haemodynamic instability
✗Type 1 diabetes — risk of unopposed glucagon effect worsening ketosis
✗Severe hepatic impairment (Child-Pugh C)
✗Pregnancy and breastfeeding
✗Concurrent GLP-1 or GIP agonist therapy (semaglutide, tirzepatide) — receptor overlap, no additive benefit

Clinical Notes

Retatrutide is currently an investigational compound (Phase 3 trials ongoing, Eli Lilly); it is not yet approved by EMA or FDA. Compounded/research-grade versions are available but quality varies significantly — only use with full Certificate of Analysis (COA). The 48-week titration mirrors the Phase 2 SURMOUNT-like study design. BPC-157 as a supporting peptide is evidence-based for GI mucosal protection and may materially reduce dropout due to GI intolerance during the critical titration phase. Thymosin Alpha-1 addresses the documented transient immune suppression during rapid hypocaloric weight loss (>1 kg/week). Retatrutide should be positioned as a last-line agent after semaglutide and tirzepatide failure, or as a primary choice in patients with BMI >40 where aggressive weight loss is clinically necessary.

Case Study

Clinical Practice Example

Female, 44, BMI 41.2, T2DM (HbA1c 7.8%), hypertension, MASLD confirmed on ultrasound. Previously tried semaglutide 2.4 mg for 12 months (lost 9% body weight, plateau reached, HbA1c 7.1%). Switched to Retatrutide with BPC-157 500 mcg/day throughout titration. Thymosin Alpha-1 added at week 6. Week 12: weight −8.1 kg (−7.3%), GI side effects mild and resolving. Week 24: weight −18.4 kg (−16.6%), HbA1c 6.3%, LDL −22%, liver echogenicity normalising. Week 48: total weight loss 26.7 kg (−24.1%), HbA1c 5.7% (pre-diabetes range), antihypertensive medication reduced. No significant adverse events. BPC-157 attributed by patient as key to tolerating dose escalation to 12 mg.

← Back to all protocols